Article 2
Could GLP-1 Receptor Agonists Be Associated with a Lower Risk of Tuberculosis in Type 2 Diabetes?
People living with type 2 diabetes have an increased risk of developing tuberculosis (TB), making infection prevention an important aspect of their long-term care. While glucose-lowering medications are primarily prescribed to manage blood sugar levels, emerging research suggests that some treatments may also be associated with differences in infection risk. A study recently published in Nature Communications, investigated the relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and tuberculosis risk. Using electronic health records from 143 healthcare organisations across multiple countries between 2017 and 2025, researchers conducted a multicentre cohort study comparing people receiving GLP-1 RAs with those prescribed sulfonylureas, metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT2) inhibitors. Propensity score matching and time-to-event analyses were used to assess TB risk over a follow-up period of up to five years.
The findings showed that GLP-1 RA use was consistently associated with a lower risk of tuberculosis compared with the other medication groups. The incidence was 0.68 versus 1.67 cases per 1,000 person-years compared with sulfonylureas, 0.65 versus 1.31 compared with metformin, and 0.73 versus 1.71 compared with DPP-4 inhibitors. Compared with SGLT2 inhibitors, the difference was smaller but remained statistically significant (0.89 versus 1.02 cases per 1,000 person-years). These results suggest a possible additional benefit of GLP-1 RAs beyond their established role in glucose management. However, this was an observational study based on electronic health records, and the findings establish an association rather than a cause-and-effect relationship. Further prospective and mechanistic studies are needed to determine whether GLP-1 RAs directly influence susceptibility to tuberculosis. These findings are promising but are not sufficient to recommend GLP-1 RAs specifically for TB prevention.